ThierryM.JahanMD

Oncology • San Francisco, CA

Endocrine Cancer, Hematologic Oncology, Sarcoma

Professor of Medicine Thoracic Oncology UCSF-Helen Diller Family Comprehensive Cancer Center

Join to view full profile

Dr. Jahan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jahan's full profile

Already have an account?

Office
1600 Divisadero St
San Francisco, CA 94143
Phone+1 415-353-9888

Fax+1 415-353-7023

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1991 - 1994
Cedars-Sinai Medical CenterFellowship, Internal Medicine/Kennamer Fellowship UCLA, 1990 - 1991
Cedars-Sinai Medical CenterResidency, Internal Medicine, 1987 - 1990
George Washington University School of Medicine and Health SciencesClass of 1987

Certifications & Licensure

CA State Medical License 1989 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
America's Top Doctors Castle Connolly, 2008-2009
America's Top Doctors for Cancer Castle Connolly, 2007-2008
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma Start of enrollment: 2003 Jul 01
Completed
Phase 2
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network Start of enrollment: 2010 Nov 01
Terminated
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer Start of enrollment: 2020 Sep 11
Recruiting
Not Applicable
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

561 citations
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Paul Baas, Arnaud Scherpereel, Anna K. Nowak, Nobukazu Fujimoto, Solange Peters
Lancet. 2021-01-30
193 citations
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
Mrinal M. Gounder, Patrick Schöffski, Robin L. Jones, Mark Agulnik, Gregory M. Cote
The Lancet. Oncology. 2020-11-01
345 citations
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
Ashley Maynard, Caroline E. McCoach, Julia K Rotow, Lincoln Harris, Franziska Haderk
Cell. 2020-09-03

Press Mentions

GO2 Foundation for Lung Cancer Recognizes the Lung Cancer Community at Simply the Best XV Virtual GalaNovember 15th, 2020
International Mesothelioma Conference Will Kick off at UCLASeptember 19th, 2016
Novel Vaccine Added to Chemotherapy Improves Patient Outcomes in MesotheliomaApril 15th, 2016

Professional Memberships

American College of Physicians - ACP
Member

Other Languages

Spanish, French